Navigation Links
John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
Date:9/26/2013

HACKENSACK, N.J., Sept. 26, 2013 /PRNewswire/ -- Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, has just published two important papers in relapsed/refractory mantle-cell lymphoma (MCL) in the Journal of Clinical Oncology and New England Journal of Medicine. MCL is a difficult subtype of non-Hodgkin lymphoma, where patients often become chemoresistant after responding to initial therapy.

Dr. Goy, an international expert in the field, led the lenalidomide global pivotal trial known as MCL-001 or EMERGE trial. Lenalidomide belongs to a category of immunomodulators that is first-in-class approved for lymphoma. This Phase II study showed that lenalidomide induced rapid and prolonged response in patients who were heavily pretreated regardless of the number of their prior regimens and with a median duration of response of more than 16 months. Many of these patients had also been refractory to their last prior therapy. The EMERGE trial results were published in the leading Journal of Clinical Oncology ("Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study" JCO September 2013).

"This trial led to the recent approval by the FDA of lenalidomide as the first oral compound available for that disease addressing a definite unmet need for these patients," said Andre Goy, M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "Lenalidomide is only the second drug ever approved for the treatment of mantle-cell lymphoma."

The second study was published in the New England Journal of Medicine a few weeks ago in collaboration
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
2. New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Laser-Proton Therapy Working Group Takes Second Look at Ways to Lower Cost of Advanced Cancer Treatment
5. APPLIED INTEGRIN SCIENCES, INC. LAUNCHES CROWDFUNDING CAMPAIGN TO RAISE FUNDS FOR ITS CANCER DRUG DEVELOPMENT PROGRAM
6. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
7. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
8. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
9. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
10. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
11. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group finds ... United States will increase to a value ... primarily driven by expansion in the large direct energy ... will be increasingly adopted due to the advantages they ... Other key findings from Decision Resources Group,s coverage of ...
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
(Date:12/22/2014)... OH (PRWEB) December 22, 2014 Explorys, ... three additions to its leadership team: Greg Yarrington as ... of Engineering, and Patrick Wells as Vice President of ... to add 80 new jobs in 2015 to support ... expansion of its platform-as-a-service offerings, and growth of its ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 BellasDress.com offers ... more for women. Today, it announces its BellasDress ... products at its online store. , BellasDress is a ... benefits to its fans through a series of promotions. ... for every customer. , “We are proud of ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... development by a team of researchers at the University of ... medical procedures. , The system works by using a Web-based ... children from the procedures that cause the pain. The distractions ... watching a video, talking, or playing a game. , The ...
... is proud to announce,that President and CEO Humberto ... Jury President for North America. Jury members for ... their,achievements in the business, non-profit and academic fields, ... The awards, an annual distinction supporting innovative woman-led,business ...
... to Brooke Army Medical Center, RESTON, Va., ... ), an information technology and network solutions (IT),company, ... competitive task order under,the US Army,s HRsolutions Indefinite ... and Support to provide,services to Brooke Army Medical ...
... Illinois at Chicago has been named one of 10 ... consumers and clinicians make critical treatment decisions about therapeutic ... of the Agency for Healthcare Research and Quality,s Center ... It will design and test systems to optimize drug ...
... Oct. 16 (HealthDay News) -- A new gene associated with ... Dmp1 gene may help improve understanding of what ... , The Wake Forest University School of Medicine researchers analyzed ... the Dmp1 gene -- which normally works to ...
... 16 Starpharma,Holdings Ltd (ASX: SPL, Pink Sheets: ... SSL International plc (LSE: SSL), owner of Durex(R), ... which a commercial licence will be negotiated,sets out ... coating.,Undisclosed fees are payable to Starpharma under the ...
Cached Medicine News:Health News:UI researchers seek to ease children's pain during medical procedures 2Health News:UI researchers seek to ease children's pain during medical procedures 3Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 2Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 3Health News:SI International Awarded $4 Million Army HRsolutions Task Order 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 3Health News:New UIC center to study drug choices, safety 2Health News:Researchers ID New Gene Linked to Lung Cancer 2Health News:Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms 2
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
...
Medicine Products: